These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35027368)

  • 1. SV2A PET Imaging Is a Noninvasive Marker for the Detection of Spinal Damage in Experimental Models of Spinal Cord Injury.
    Bertoglio D; Halloin N; Lombaerde S; Jankovski A; Verhaeghe J; Nicaise C; Staelens S
    J Nucl Med; 2022 Aug; 63(8):1245-1251. PubMed ID: 35027368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
    Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S
    J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging.
    Chen MK; Mecca AP; Naganawa M; Finnema SJ; Toyonaga T; Lin SF; Najafzadeh S; Ropchan J; Lu Y; McDonald JW; Michalak HR; Nabulsi NB; Arnsten AFT; Huang Y; Carson RE; van Dyck CH
    JAMA Neurol; 2018 Oct; 75(10):1215-1224. PubMed ID: 30014145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET.
    Thomsen MB; Jacobsen J; Lillethorup TP; Schacht AC; Simonsen M; Romero-Ramos M; Brooks DJ; Landau AM
    J Cereb Blood Flow Metab; 2021 Apr; 41(4):819-830. PubMed ID: 32538280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and Preclinical Evaluation of 11C-UCB-J as a PET Tracer for Imaging the Synaptic Vesicle Glycoprotein 2A in the Brain.
    Nabulsi NB; Mercier J; Holden D; Carré S; Najafzadeh S; Vandergeten MC; Lin SF; Deo A; Price N; Wood M; Lara-Jaime T; Montel F; Laruelle M; Carson RE; Hannestad J; Huang Y
    J Nucl Med; 2016 May; 57(5):777-84. PubMed ID: 26848175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Imaging of Regional Brain Volumes, SV2A, and Glucose Metabolism In Huntington's Disease.
    Delva A; Van Laere K; Vandenberghe W
    Mov Disord; 2023 Aug; 38(8):1515-1526. PubMed ID: 37382295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of [
    Puuvuori E; Rokka J; Carlsson PO; Li Z; Eriksson J; Eriksson O
    Sci Rep; 2021 Dec; 11(1):24466. PubMed ID: 34963683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vivo evaluation of [
    Li S; Cai Z; Zhang W; Holden D; Lin SF; Finnema SJ; Shirali A; Ropchan J; Carre S; Mercier J; Carson RE; Nabulsi N; Huang Y
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1952-1965. PubMed ID: 31175396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET Tracers.
    Constantinescu CC; Tresse C; Zheng M; Gouasmat A; Carroll VM; Mistico L; Alagille D; Sandiego CM; Papin C; Marek K; Seibyl JP; Tamagnan GD; Barret O
    Mol Imaging Biol; 2019 Jun; 21(3):509-518. PubMed ID: 30084043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical PET Studies of [
    Thomsen MB; Schacht AC; Alstrup AKO; Jacobsen J; Lillethorup TP; Bærentzen SL; Noer O; Orlowski D; Elfving B; Müller HK; Brooks DJ; Landau AM
    Mol Imaging Biol; 2020 Oct; 22(5):1290-1300. PubMed ID: 32514885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation and noninvasive kinetic modeling of [
    Bertoglio D; Verhaeghe J; Miranda A; Kertesz I; Cybulska K; Korat Š; Wyffels L; Stroobants S; Mrzljak L; Dominguez C; Liu L; Skinbjerg M; Munoz-Sanjuan I; Staelens S
    J Cereb Blood Flow Metab; 2020 Jun; 40(6):1351-1362. PubMed ID: 31307287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of synaptic loss in mouse models of β-amyloid and tau pathology using [
    Vogler L; Ballweg A; Bohr B; Briel N; Wind K; Antons M; Kunze LH; Gnörich J; Lindner S; Gildehaus FJ; Baumann K; Bartenstein P; Boening G; Ziegler SI; Levin J; Zwergal A; Höglinger GU; Herms J; Brendel M
    Neuroimage Clin; 2023; 39():103484. PubMed ID: 37541098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced synaptic vesicle protein 2A binding in temporal lobe epilepsy: A [
    Finnema SJ; Toyonaga T; Detyniecki K; Chen MK; Dias M; Wang Q; Lin SF; Naganawa M; Gallezot JD; Lu Y; Nabulsi NB; Huang Y; Spencer DD; Carson RE
    Epilepsia; 2020 Oct; 61(10):2183-2193. PubMed ID: 32944949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of imaging synaptic density in the human spinal cord using [
    Rossano S; Toyonaga T; Bini J; Nabulsi N; Ropchan J; Cai Z; Huang Y; Carson RE
    EJNMMI Phys; 2022 May; 9(1):32. PubMed ID: 35503134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of pre-synaptic density networks using [
    Akkermans J; Zajicek F; Miranda A; Adhikari MH; Bertoglio D
    Neuroimage; 2022 Dec; 264():119771. PubMed ID: 36436710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sapap3 deletion causes dynamic synaptic density abnormalities: a longitudinal [
    Glorie D; Verhaeghe J; Miranda A; De Lombaerde S; Stroobants S; Staelens S
    EJNMMI Res; 2020 Nov; 10(1):140. PubMed ID: 33185747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring with [
    Serrano ME; Bahri MA; Becker G; Seret A; Germonpré C; Lemaire C; Giacomelli F; Mievis F; Luxen A; Salmon E; Rogister B; Raedt R; Plenevaux A
    Mol Imaging Biol; 2020 Oct; 22(5):1197-1207. PubMed ID: 32206990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [
    Zheng C; Holden D; Zheng MQ; Pracitto R; Wilcox KC; Lindemann M; Felchner Z; Zhang L; Tong J; Fowles K; Finnema SJ; Nabulsi N; Carson RE; Huang Y; Cai Z
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1482-1496. PubMed ID: 34761284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical In Vitro and In Vivo Characterization of Synaptic Vesicle 2A-Targeting Compounds Amenable to F-18 Labeling as Potential PET Radioligands for Imaging of Synapse Integrity.
    Patel S; Knight A; Krause S; Teceno T; Tresse C; Li S; Cai Z; Gouasmat A; Carroll VM; Barret O; Gottmukkala V; Zhang W; Xiang X; Morley T; Huang Y; Passchier J
    Mol Imaging Biol; 2020 Aug; 22(4):832-841. PubMed ID: 31728839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imaging of Synaptic Density in Neurodegenerative Disorders.
    Carson RE; Naganawa M; Toyonaga T; Koohsari S; Yang Y; Chen MK; Matuskey D; Finnema SJ
    J Nucl Med; 2022 Jun; 63(Suppl 1):60S-67S. PubMed ID: 35649655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.